APC.V - Advanced Proteome Therapeutics Corporation

TSXV - TSXV Delayed Price. Currency in CAD

Advanced Proteome Therapeutics Corporation

650 Albany Street
Boston, MA 02118
United States

Full Time Employees

Key Executives

Dr. Randal D. Chase Ph.D.Pres, CEO & DirectorN/AN/A67
Dr. Alexander Krantz Ph.D.Founder, COO, Chief Scientific Officer, VP of Research & Director175kN/A76
Mr. Kenneth Clifford PhilippeChief Financial Officer14.36kN/A65
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. The company develops and commercializes a platform that is intended to use protein modification technologies to create human protein pharmaceuticals with therapeutic properties. Its proprietary technology targets cancerous tumors and avoids destroying normal cells. The company has collaboration with Heidelberg Pharma AG; and a collaboration and option agreement with ImmunoBiochem Corporation to develop antibody-drug conjugates. Advanced Proteome Therapeutics Corporation is headquartered in Boston, Massachusetts.

Corporate Governance

Advanced Proteome Therapeutics Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.